By Carlo Martuscelli

 

Roche Holding AG (ROG.EB) said Monday that a study of its cancer drug Tecentriq had met its objectives, with the drug showing efficacy in patients with previously untreated, advanced bladder cancer.

The German company said that data from the Imvigor130 phase 3 clinical trial showed Tecentriq combined with chemotherapy improved the amount of time before disease progression when compared with chemotherapy alone. Patients in the study had a form of bladder cancer called urothelial carcinoma.

Tecentriq is an immunotherapy--a type of medicine that is designed to help the immune system fight tumor cells.

 

Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com

 

(END) Dow Jones Newswires

September 30, 2019 11:05 ET (15:05 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From May 2020 to Jun 2020 Click Here for more Roche (QX) Charts.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Jun 2019 to Jun 2020 Click Here for more Roche (QX) Charts.